Eden Compounded GLP-1vsIvim Health Compounded GLP-1

You self-administer a once-weekly subcutaneous injection of compounded semaglutide or tirzepatide. Semaglutide activates GLP-1 receptors; tirzepatide activates both GIP and GLP-1 receptors. The result is slower stomach emptying, increased fullness, and reduced appetite, which lowers calorie intake. An Eden provider sets and titrates the dose over time.

You take a weekly subcutaneous injection of compounded semaglutide (a GLP-1 receptor agonist) or compounded tirzepatide (a dual GIP/GLP-1 agonist). These slow gastric emptying and increase satiety signaling, reducing appetite and calorie intake. Ivim providers tailor your dose individually rather than using a fixed schedule, adjusting as tolerated.

Eden's medications share active ingredients with branded drugs studied in major trials: STEP 1 showed branded semaglutide produced roughly 14.9% average weight loss over 68 weeks, and SURMOUNT-1 showed branded tirzepatide produced up to about 20.9% over 72 weeks. Compounded versions are not independently FDA-tested, so these figures are context, not a promise. Individual results vary.

Ivim's compounded medications use the same active molecules as branded GLP-1 drugs. In STEP 1, branded semaglutide produced about 14.9% average weight loss over 68 weeks; in SURMOUNT-1, branded tirzepatide produced up to about 20.9% over 72 weeks. Compounded formulations are not separately FDA-tested, so these are reference points only. Individual results vary.

Gastrointestinal side effects (nausea, constipation, diarrhea) are the most common and usually improve with slow dose titration. Serious but uncommon risks include pancreatitis and gallbladder issues. Because the medication is compounded rather than FDA-approved, report any unexpected symptoms to your provider. This is educational, not medical advice.

The most common effects are gastrointestinal (nausea, diarrhea, constipation, fatigue) and usually ease with gradual titration. Serious but uncommon risks include pancreatitis and gallbladder disease. As a compounded product, dosing-error and quality risks exist, so report unusual symptoms to your provider. This is educational information, not medical advice.

Plan for $149 the first month and $229/month thereafter for semaglutide, or $249 then $329/month for tirzepatide, as of May 2026. Multi-month bundles cut the effective monthly rate. The price is all-in (visit, medication, free shipping) and is not covered by insurance because the product is compounded.

Effective combined cost is about $150/month for semaglutide and ~$208/month for tirzepatide as of May 2026, built from a $75/mo membership (first month free) plus medication bundles ($379-$499 for semaglutide, $550-$900 for tirzepatide). HSA/FSA cards and Klarna financing are accepted. Compounded medication is not insurance-covered.

For US adults seeking medical weight management who pass a telehealth clinical review. Not for people with a history of medullary thyroid carcinoma or MEN 2, and not for use in pregnancy. Availability and product options vary by state.

For US adults seeking medical weight management who pass Ivim's telehealth clinical evaluation. Not appropriate for people with a personal or family history of medullary thyroid carcinoma or MEN 2, or during pregnancy. State availability varies.